Elanco Animal Health Inc (ELAN) Stock
ELAN has an Alpha Score of 39 out of 100 (weak), computed on Nov 4, 2026 from 2 of 4 sub-scores. 7 members of Congress disclosed 17 trades in ELAN since 2018: 9 purchases and 7 sales, most recently Valerie Hoyle (sale, Sep 23, 2025). 6 of the hedge funds AlphaScala tracks reported ELAN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $237.94M. Company insiders reported 3 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 6, 2026.
What is ELAN's Alpha Score?
How it works →Alpha Score of 39 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Elanco Animal Health Inc (ELAN)?
Most recent: Valerie Hoyle (sale, Sep 23, 2025); records start Sep 21, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Val Hoyle D-OR · House | 2025-09-23 | sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-03-06 | partial sale | $1k – $15k |
| Susie Lee D-NV · House | 2022-11-30 | sale | $1k – $15k |
| Susie Lee D-NV · House | 2021-06-21 | purchase | $1k – $15k |
| Susie Lee D-NV · House | 2021-06-10 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-12-21 | purchase | $1k – $15k |
| Katherine Clark D-MA · House | 2020-11-05 | sale | $1k – $15k |
| Katherine Clark D-MA · House | 2020-10-22 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all ELAN political trades →Which hedge funds own ELAN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 9.67M | $237.94M | +120% |
| Marshall Wace | 4.43M | $109.08M | +221% |
| Millennium Management Israel Englander | 2.73M | $67.08M | +282% |
| Maverick Capital Lee Ainslie | 98K | $2.41M | -32% |
| D.E. Shaw David Shaw | 89K | $2.19M | -39% |
| Bridgewater Associates Ray Dalio | 83K | $2.04M | -4% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Elanco Animal Health Inc insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Bettington Timothy J | SEE REMARKS | SELL | 4.3K | $100K |
| Aug 20, 26 | Kurzius Lawrence Erik | Director | BUY | 40.0K | $936K |
| Aug 18, 26 | O'Neill Shiv | GC AND CORP SEC | BUY | 4.0K | $94K |
| Aug 12, 26 | Harrington Michael J | Director | BUY | 5.0K | $109K |
| Aug 7, 26 | Herendeen Paul | Director | BUY | 10.0K | $237K |
| Aug 7, 26 | Vanhimbergen Robert M | EVP and CFO | BUY | 4.2K | $97K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are ELAN's key statistics?
Key statistics as of Oct 31, 2026
How does ELAN's valuation compare with the Healthcare sector?
| Metric | ELAN | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -3.96% | 4.31% | 164 |
| Return on equity | -3.02% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
ELAN price chart
Powered by TradingViewWhat does Elanco Animal Health Inc do?
Elanco Animal Health Incorporated is a leading global pharmaceutical company specializing in animal health. Its primary function is the development and delivery of innovative products and solutions to prevent and treat diseases in both companion animals and livestock, including dogs, cats, cattle, poultry, swine, sheep, and aquaculture species. With a heritage dating to 1954, Elanco combines six decades of research-driven expertise and operates across more than 90 countries, earning over half its revenue from international markets. The company serves veterinarians, farmers, and pet owners through a diverse portfolio that addresses significant animal health challenges, improving animal welfare while indirectly supporting food security and public health. Elanco’s ongoing commitment to research and sustainable practices positions it as a critical partner in enhancing animal well-being, supporting the agricultural sector, and advancing the global animal health industry.